AAAAI: Omalizumab as Effective as Multifood Oral Immunotherapy for Individuals With Food Allergy

Follow Drugslib on

By Elana Gotkine HealthDay Reporter

Medically reviewed by Drugs.com

via HealthDay

FRIDAY, March 6, 2026 -- Individuals with one to three allergenic foods are able to introduce and continue eating allergenic foods at 12 months after multifood oral immunotherapy (mOIT) or omalizumab, according to a study presented at the annual meeting of the American Academy of Allergy, Asthma & Immunology, held from Feb. 27 to March 2 in Philadelphia.

R. Sharon Chinthrajah, M.D., from Stanford University in California, and colleagues examined dietary consumption (DC) feasibility after about 52 weeks of mOIT or omalizumab (29 and 51 participants, respectively) for one to three allergenic foods.

The researchers found that using daily diaries at three and six months, DC plan success rates (consuming ≥300 mg/day of allergenic foods) at three and six months showed no significant between-group differences across all foods (77 and 65 percent, respectively, after mOIT; 66 and 63 percent, respectively, after omalizumab). Comparable outcomes were seen for individual allergens (e.g., peanut: 77 and 65 percent after mOIT; 67 and 60 percent after omalizumab). No group differences were seen in success rates at three, six, nine, or 12 months across foods or individual allergens based on study team evaluations. Among 52 participants who remained on DC plans for all three foods for 12 months, safety was similar between groups. Similar proportions of patients experienced any adverse event in both groups (86 and 93 percent after mOIT and after omalizumab, respectively).

"After approximately one year of treatment with either omalizumab facilitated multifood oral immunotherapy or omalizumab alone, more than 60 percent of participants were successfully eating their allergenic foods regularly," Chinthrajah said in a statement. "Both treatment approaches appear to open a pathway to dietary inclusion with comparable safety and success."

Several authors disclosed ties to the biopharmaceutical industry.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

Source: HealthDay

Posted : 2026-03-07 01:38

Read more

Disclaimer

Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

Popular Keywords